PreveCeutical Medical Inc.
PRVCF
$0.025
-$0.0005-1.96%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.41% | -19.78% | 16.91% | -30.82% | -39.99% |
| Depreciation & Amortization | 5.48% | 2.78% | -27.45% | -20.65% | -12.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.11% | -18.79% | 13.83% | -27.67% | -36.05% |
| Operating Income | -62.11% | 18.79% | -13.83% | 27.67% | 36.05% |
| Income Before Tax | -45.40% | 9.03% | -158.04% | -13.45% | 14.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.40% | 9.03% | -158.04% | -13.45% | 14.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.40% | 9.03% | -158.04% | -13.45% | 14.13% |
| EBIT | -62.11% | 18.79% | -13.83% | 27.67% | 36.05% |
| EBITDA | -62.83% | 19.01% | -14.58% | 27.71% | 36.27% |
| EPS Basic | -53.33% | 5.88% | -216.67% | -13.33% | 16.67% |
| Normalized Basic EPS | -40.00% | 9.09% | -200.00% | -22.22% | 9.09% |
| EPS Diluted | -53.33% | 5.88% | -216.67% | -13.33% | 16.67% |
| Normalized Diluted EPS | -40.00% | 9.09% | -200.00% | -22.22% | 9.09% |
| Average Basic Shares Outstanding | 0.23% | 0.19% | 0.47% | 0.96% | 1.46% |
| Average Diluted Shares Outstanding | 0.23% | 0.19% | 0.47% | 0.96% | 1.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |